½Å°úÇÐ/öÇÐ
Ãʽɸ®ÇÐ/ÀáÀç´É·Â
UFO/½Å¹°¸®ÇÐ
¿ÀÄÃƼÁò/¹Ì½ºÅ͸®

°úÇÐÀû, ºñ°úÇÐÀû ÀÇÇÐ
µ¿¼­¾ç ´ëüÀÇÇÐ

âÁ¶·Ð/°úÇÐÀû »ç½Ç¼º
âÁ¶·Ð/öÇаú Á¤Ä¡

½ºÄÎƽ½º/±âŸ ÁÖÁ¦
KOPSA ¹Ú¹°°ü

 

´ëÁ߸Åü ¸ð´ÏÅ͸µ
Áú¹®°ú ´ä

Åä·Ð¹æ¹ý
Åä·Ð»ç·Ê

¿¬±¸È¸¿ø °Ô½ÃÆÇ
¿¬±¸À§¿ø °Ô½ÃÆÇ

 

°úÇÐÀû, ºñ°úÇÐÀû ÀÇÇÐ
   
  ³ì½ÊÀÚ ¹®Á¦(24) Æä¶ó¹Ìºñ¸£ ±Ù ÁÖ»çÁ¦ ÀÓ»ó ½ÇÆÐÀÇ ±³ÈÆ
  ±Û¾´ÀÌ : kopsa     ³¯Â¥ : 09-06-20 09:04     Á¶È¸ : 3752    
³ì½ÊÀÚ ¹®Á¦(24) Æä¶ó¹Ìºñ¸£ ±Ù ÁÖ»çÁ¦ ÀÓ»ó ½ÇÆÐÀÇ ±³ÈÆ

³ì½ÊÀÚ »çÀÌÆ®¿¡ µé¾î°¡ º¸´Ï 2009³â 6¿ù 9ÀÏÀÚ ¡°³ì½ÊÀÚ, ½ÅÁ¾ÇÃ·ç ¹é½Å ¾ç»ê Áغñ µ¹ÀÔ¡± Á¦¸ñÀÇ º¸µµ¹®ÀÌ ÀÖ½À´Ï´Ù(¾Æ·¡ Àü¹® ÂüÁ¶). ±¹°¡ÀûÀ¸·Î ºñ»ó»çÅ¿¡ ´ëºñÇÑ ¹é½Å »ý»êÀº Áß¿äÇϱ⠶§¹®¿¡ Á¤ºÎ¿¡¼­µµ ³ì½ÊÀÚÀÇ ¹é½Å °øÀå °Ç¼³À» Áö¿øÇß½À´Ï´Ù. ¿äÁîÀ½ ¾ð·Ð º¸µµ¿¡´Â ±×°ÍÀÌ Ã·´Ü ½Ã¼³ÀÓÀ» º¸¿©Áִµ¥ ¿ì¸®µµ ¾ÕÀ¸·Î ¾à Á¦Á¶¸¦ ¹Ì±¹ÀÇ GMP ¼öÁØÀ¸·Î °ü¸®ÇÏ°Ú´Ù°í ÇßÀ¸´Ï ÁÁÀº Çö»óÀÓ¿¡ Ʋ¸²¾ø½À´Ï´Ù.       

1. ½ÅÁ¾ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ Æä¶ó¹Ìºñ¸£?

±×·¯³ª º¸µµ¹®¿¡´Â ¾Æ·¡¿Í °°Àº ÀÌ»óÇÑ ´ë¸ñÀÌ ÀÖ½À´Ï´Ù.   
 
¡°ÇÑÆí ³ì½ÊÀÚ´Â ¹Ì±¹, ÀϺ», ´ë¸¸ µî°ú ÇÔ²² ÁøÇàÇØ ¿Â »õ·Î¿î ½ÅÁ¾ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ÀÎ `Æä¶ó¹Ìºñ¸£`ÀÇ ±Û·Î¹ú ÀÓ»ó 3»óÀ» ÃÖ±Ù ¿Ï·áÇÏ°í ³»³â »ó¹Ý±â Áß ÃÖÁ¾Çã°¡¸¦ ÁøÇàÇÒ °ÍÀ¸·Î ¾Ë·ÁÁ³´Ù. ÀÌ¿¡ µû¶ó ³ì½ÊÀÚ´Â ÃÖ±Ù ÀÏ°í ÀÖ´Â ½ÅÁ¾ÀÎÇ÷翣ÀÚÀÇ ¿¹¹æÀ» À§ÇÑ ¹é½Å°ú ´õºÒ¾î ÀÎÇ÷翣ÀÚ¿¡ ´ëÇÑ »õ·Î¿î Ä¡·áÁ¦¿¡ À̸£±â±îÁö ±¹³» ÀÎÇ÷翣ÀÚ ¹æ¾îü°èÀÇ ¿Ïº®ÇÑ ±¸ÃàÀ» ÀÌ·ç°Ô µÈ´Ù.¡±

Æä¶ó¹Ìºñ¸£´Â ÀÏ¹Ý µ¶°¨ ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ ÀÓ»ó½ÃÇèÀε¥ ±× µ¿¾È Á¶·ùµ¶°¨ Ä¡·áÁ¦¶ó°í ÇÏ´õ´Ï À̹ø¿¡´Â ¡°»õ·Î¿î ½ÅÁ¾ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦¡±¶ó°í ÇÏ¿´½À´Ï´Ù. À̹ø¿¡ ¸ß½ÃÄÚ¿¡¼­ ½ÃÀÛµÈ ±× ½ÅÁ¾Ç÷çÀÇ »õ·Î¿î Ä¡·áÁ¦¶ó´Â ¸»·Î µé¸®´Âµ¥, ¶Ç´Â ±âÁ¸¿¡´Â ¾ø¾ú´ø º¯Á¾ ¹ÙÀÌ·¯½º¿¡ ÀÇÇÑ ÀÎÇ÷翣ÀÚÀÇ »õ·Î¿î Ä¡·áÁ¦¶ó´Â ¸»Àΰ¡¿ä? Æä¶ó¹Ìºñ¸£´Â ¾ÆÁ÷ ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦·Î »ç¿ëÀÌ °¡´ÉÇÑ ´Ü°è°¡ ¾Æ´Ï¸ç ¡°±¹³» ÀÎÇ÷翣ÀÚ ¹æ¾îü°èÀÇ ¿Ïº®ÇÑ ±¸ÃࡱÀ̶ó´Â Ç¥ÇöÀº °úÀåÀÔ´Ï´Ù.   

2. °èÀý¼º µ¶°¨ ¹é½Å ±×¸®°í Ç÷ç¹Ì½ºÆ® 

³ì½ÊÀÚ°¡ ½ÅÁ¾Ç÷ç Àü¿¡ »õ·Î¿î °øÀå¿¡¼­ »ý»êÀ» ½ÃÀÛÇß´Ù´Â °èÀý¼º µ¶°¨ ¹é½Å°ú °ü·ÃÇÏ¿©  ±× µ¿¾È ¹é½ÅÀ» °ø±ÞÇØ¿Â ¾÷ü´Â ¿Ü±¹¿¡¼­ ¿ø·á¸¦ »ç´Ù Á¦Á¶ÇÏ´Â ±â¾÷ü, ¶Ç´Â ¿Ü±¹ÀÇ »ý»êÇ°À» Á÷Á¢ ¼öÀÔÇÏ´Â ¾÷ü¸¦ ¸Á¶óÇÏ¿´´Âµ¥, À̹ø¿¡ Á÷Á¢ »ý»êÇÏ´Â ³ì½ÊÀÚ¿¡¼­´Â ¾Æ¸¶µµ Á¤ºÎ Á¶´ÞÇ°ÀÏ °ÍÀÌÁö¸¸ ÀÏÁ¤ ƯÇý¸¦ ¿ä±¸ÇÒ °Í °°½À´Ï´Ù. ±×·¯³ª °æÀï ÀÔÂûÀÌ ¿øÄ¢ÀÏ °ÍÀ¸·Î º¸À̴µ¥ ´Ù¸£´Ù¸é ¾Ë·ÁÁֽñ⠹ٶø´Ï´Ù. 

¿ÃÇØ °ø±ÞµÇ´Â ¹é½Å¿¡´Â ÄÚ¿¡ »Ñ¸®´Â ÇüÅÂÀÇ ¹é½Åµµ ÀÖ´Ù°í Çϴµ¥ ÀÌ°ÍÀº Ç÷ç¹Ì½ºÆ®(FluMist)¶ó´Â °ÍÀÔ´Ï´Ù. ÀÏ¹Ý µ¶°¨ ¹é½ÅÀº ¹ÙÀÌ·¯½º¸¦ Á×ÀÎ »ç¹é½ÅÀε¥ ÀÌ°ÍÀº ¾àµ¶È­½ÃŲ »ý¹é½Å ÀÔ´Ï´Ù.  »ç¿ë ¿¬·É¿¡¼­ 6°³¿ù À¯¾Æ ÀÌ»ó¿¡ Á¢Á¾ÇÏ´Â ÀÏ¹Ý ¹é½Å°ú´Â ´Þ¸® 2-49¼¼·Î Á¦¾àÀÌ ÀÖ½À´Ï´Ù. 50¼¼ À̻󿡴 ȿ°ú°¡ ¾ø´Ù°í ÇÕ´Ï´Ù. ÁÖ»ç´ë½Å¿¡ ÄÚ¿¡ »Ñ¸°´Ù´Â ¿Ü¿¡ Ưº°ÇÏÁö ¾Ê¾Æ º¸ÀÔ´Ï´Ù.

±×·±µ¥ ¿ì¸®ÀÇ ¾ð·Ð¿¡¼­´Â ¿ÃÇØ µ¶°¨ ¹é½Å °ø±Þ°ú °ü·ÃÇÏ¿© ÄÚ¿¡ »Ñ¸®´Â Ç÷ç¹Ì½ºÆ®µµ ÀÖ´Ù°í ÇÏ¸ç ³ì½ÊÀÚ¿¡¼­ ¼öÀÔÇÑ´Ù°í µ¡ºÙÀÔ´Ï´Ù. º°·Î Áß¿äÇÏÁö ¾ÊÀº ÀÌ·± °ÍÀº ¾î°¼­ º¸µµÇÏ´ÂÁö? ´Ù½Ã Æä¶ó¹Ìºñ¸£¸¦ »ó±â½Ãŵ´Ï´Ù. ·Î¿­Æ¼¸¦ ÁöºÒÇÏ¸ç ±¹³» ÆǸŠµ¶Á¡±ÇÀ» ±¸ÀÔÇÑ °ÍÀ», ¾ÆÁ÷ ÀÓ»ó ÁßÀÎ °ÍÀ» ³ì½ÊÀÚ´Â ¾ó¸¶³ª ±¤°íÇÏ°í ÀÖ½À´Ï±î? ¾î¶² ÀÎÇ÷翣ÀÚ¿¡µµ È¿°ú°¡ ÀÖÀ» °Íó·³ ¸»ÀÔ´Ï´Ù.   
 
3. Æä¶ó¹Ìºñ¸£ ±Ù ÁÖ»çÁ¦ ÀÓ»ó ½ÇÆÐ

¾Æ·¡ ÷ºÎÇÑ 2009³â 5¿ù 8ÀÏ AP Åë½Å ±â»ç¿¡ ÀÇÇϸé Æä¶ó¹Ìºñ¸£ ±Ù ÁÖ»çÁ¦ÀÇ ÀÓ»ó ½ÃÇèÀÌ Áß°£´Ü°è¿¡¼­ ½ÇÆзΠ³ª¿Ô½À´Ï´Ù. 405¸íÀÇ µ¶°¨ ȯÀÚ¸¦ ´ë»óÀ¸·Î Æä¶ó¹Ìºñ¸£ ±Ù ÁÖ»çÁ¦¿Í Çö󼼺¸¸¦ ½ÃÇèÇß´õ´Ï °¢±â Æò±Õ ȸº¹ ½Ã°£ÀÌ 91.1, 106.1 ½Ã°£À¸·Î Åë°èÀûÀ¸·Î À¯ÀǹÌÇÑ Â÷ÀÌ°¡ ¾ø¾ú´Ù°í Çß½À´Ï´Ù.

±Ù ÁÖ»çÁ¦¸¦ °³¹ßÇÏ·Á´Â ÀÌÀ¯´Â, Åõ¿©ÀÇ Æí¸®¼º ¶§¹®ÀÔ´Ï´Ù. ¾Æ·¡ ±â»ç¿¡´Â Ÿ¹ÌÇ÷ç(°æ±¸¿ë)³ª ¸®·»ÀÚ(ÈíÀÔÁ¦)¿Í °°ÀÌ ÀÇ»çÀÇ Ã³¹æ¿¡ ÀÇÇØ È¯ÀÚ ½º½º·Î Åõ¿©ÇÏ´Â »óȲÀ» ¸»ÇßÀ¸³ª °æ¿ì¿¡ µû¶ó¼­´Â °¡´ÉÇÒÁöµµ ¸ð¸¨´Ï´Ù. ¿©ÇÏÆ° Åë»ó ÀÔ¿ø ȯÀÚÀÇ Á¤¸Æ ÁÖ»çÁ¦º¸´Ù´Â ¿Ü·¡ ȯÀÚ¿¡µµ Æí¸®ÇÏ°Ô Åõ¿©ÇÏ´Â ±Ù ÁÖ»çÁ¦°¡ ¾à ÆǸſ¡ °æÀï·ÂÀÌ ÀÖ´Ù°í º¸¾ÒÀ» °ÍÀÔ´Ï´Ù.     

±Ù ÁÖ»çÁ¦°¡ ÀÓ»ó¿¡¼­ ½ÇÆÐÇߴµ¥ Á¤¸ÆÁÖ»çÁ¦´Â ¾î¶³Áö? ³ì½ÊÀÚ º¸µµ¹®¿¡´Â ¡°±Û·Î¹ú ÀÓ»ó 3»óÀ» ÃÖ±Ù ¿Ï·áÇÏ°í ³»³â »ó¹Ý±â Áß ÃÖÁ¾Çã°¡¸¦ ÁøÇàÇÒ °ÍÀ¸·Î ¾Ë·ÁÁ³´Ù¡±°í Çߴµ¥ È¿°ú°¡ ÀÖ´Ù°í Çصµ Á¤¸Æ ÁÖ»çÁ¦¸¦ ÀÏ¹Ý µ¶°¨ Ä¡·áÁ¦·Î ³» ³õÀ» °ÍÀÎÁö? ¾î·Á¿î À̾߱âÀÔ´Ï´Ù. Á¶·ù µ¶°¨ µî ¸» ±×´ë·Î ½ÅÁ¾Ç÷翡 È¿°ú¸¦ ±â´ëÇÒ °ÍÀÔ´Ï´Ù. ±×·¯³ª ±âÁ¸ÀÇ ¾àº¸´Ù ³ªÀ» °ÍÀÌ ¾ø´Ù¸é ¾î¶»°Ô ÇÏ°Ú´ÂÁö? ³ì½ÊÀÚ´Â Á¶¿ëÈ÷ ÁöÄѺ¸¾Æ¾ß ÇÒ °ÍÀÔ´Ï´Ù. ÀÌ°ÍÀÌ Á¦¾à±â¾÷ÀÇ ¹Ù¸¥ ÀÚ¼¼ÀÔ´Ï´Ù. (³ì½ÊÀÚ¿¡ µµ¿òÀÌ µÇ¶ó°í ÀÌ ±ÛÀ» °Ô½ÃÇÕ´Ï´Ù.)   

................................................................
³ì½ÊÀÚ, ½ÅÁ¾ÇÃ·ç ¹é½Å ¾ç»ê Áغñ µ¹ÀÔ(º¸µµ¹®) 
2009-06-09

³ì½ÊÀÚ°¡ ¿µ±¹ NIBSC(¿µ±¹±¹¸³»ý¹°ÀǾàÇ°Ç¥ÁØÈ­¿¬±¸¼Ò)¿Í ¹Ì±¹CDC(Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ)·ÎºÎÅÍ ½ÅÁ¾ÇÃ·ç ¹é½Å Á¦Á¶¿ë Á¾¹ÙÀÌ·¯½ºÁÖ(master seed)¸¦ È®º¸Çß´Ù.

ÀÌ ¹é½ÅÁ¦Á¶¿ë Á¾¹ÙÀÌ·¯½ºÁÖ´Â 6¿ù 8ÀÏ ÇöÀç Ç×°øÆíÀ¸·Î ÀÎõ°øÇ׿¡ µµÂø, Åë°üÀýÂ÷°¡ ÁøÇà ÁßÀ̸ç, 9ÀÏ ³ì½ÊÀÚ È­¼ø°øÀåÀ¸·Î ÀÔ°íµÉ ¿¹Á¤ÀÌ´Ù.

½ÅÁ¾ÇÃ·ç ±ÕÁÖ°¡ µµÂøÇÔ¿¡ µû¶ó °ð ¹é½ÅÀÇ ´ë·®»ý»êÀ» À§ÇÑ Á¦Á¶¿ë ¹ÙÀÌ·¯½º(working seed)Á¦Á¶¿¡ µ¹ÀÔÇÏ°Ô µÇ¸ç ÀÌ Á¦Á¶¿ë ¹ÙÀÌ·¯½º¸¦ Á¦Á¶Çϴµ¥ ¾à 15ÀÏ Á¤µµ ¼Ò¿äµÉ °ÍÀ̶ó°í ¹àÇû´Ù.

ÀÌ¿¡ µû¶ó, ÀÌ´Þ ¸»±îÁö ½ÅÁ¾ÇÃ·ç ¹é½Å»ý»ê¿¡ ÇÊ¿äÇÑ ¸ðµç Áغñ¸¦ °®Ãß°Ô µÇ¸ç ´Ê¾îµµ 7¿ùºÎÅÍ ¹é½Å»ý»êÀÌ °¡´ÉÇÒ Àü¸ÁÀÌ´Ù.

ÀÌ¿Í °ü·ÃÇØ ³ì½ÊÀÚ °³¹ßº»ºÎÀå À̺´°Ç(ì°Ü¹Ëï)ºÎ»çÀåÀº, ¡°Á¤ºÎÀÇ »ý»ê ¿äûÀÌ ÀÖÀ» ½Ã Áï½Ã ½ÅÁ¾ÇÃ·ç ¹é½ÅÀ» »ý»ê, °ø±ÞÇÒ ¼ö ÀÖµµ·Ï ¿¬±¸°³¹ß ¹× »ý»êÀηÂ, ¼³ºñ µî »ý»ê¿¡ ÇÊ¿äÇÑ ¸ðµç ÁغñÀÛ¾÷ÀÌ ¿Ï·áµÆ´Ù¡±¸ç, ¡°µ¶¸³ÀûÀÎ ½ÅÁ¾ÇÃ·ç ¹é½Å »ý»ê ´É·ÂÀ» °®ÃãÀ¸·Î½á ±¹°¡ º¸°Ç¾Èº¸¿¡ À̹ÙÁöÇÒ ¼ö ÀÖÀ» °Í¡±À̶ó°í Àǹ̸¦ ¼³¸íÇß´Ù.

ÇÑÆí ³ì½ÊÀÚ´Â ¹Ì±¹, ÀϺ», ´ë¸¸ µî°ú ÇÔ²² ÁøÇàÇØ ¿Â »õ·Î¿î ½ÅÁ¾ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ÀÎ `Æä¶ó¹Ìºñ¸£`ÀÇ ±Û·Î¹ú ÀÓ»ó 3»óÀ» ÃÖ±Ù ¿Ï·áÇÏ°í ³»³â »ó¹Ý±â Áß ÃÖÁ¾Çã°¡¸¦ ÁøÇàÇÒ °ÍÀ¸·Î ¾Ë·ÁÁ³´Ù.

ÀÌ¿¡ µû¶ó ³ì½ÊÀÚ´Â ÃÖ±Ù ÀÏ°í ÀÖ´Â ½ÅÁ¾ÀÎÇ÷翣ÀÚÀÇ ¿¹¹æÀ» À§ÇÑ ¹é½Å°ú ´õºÒ¾î ÀÎÇ÷翣ÀÚ¿¡ ´ëÇÑ »õ·Î¿î Ä¡·áÁ¦¿¡ À̸£±â±îÁö ±¹³» ÀÎÇ÷翣ÀÚ ¹æ¾îü°èÀÇ ¿Ïº®ÇÑ ±¸ÃàÀ» ÀÌ·ç°Ô µÈ´Ù.
----------------------

http://finance.yahoo.com/news/BioCryst-says-flu-drug-apf-15185259.html?x=1&.v=1

BioCryst says flu drug candidate failed in trial
BioCryst slides after intramuscular peramivir caused little improvement in midstage trial

By Marley Seaman, AP Health Writer
On Friday May 8, 2009, 2:01 pm EDT
 
NEW YORK (AP) -- BioCryst Pharmaceuticals Inc. said Friday that a version of its flu drug candidate peramivir failed in a clinical trial, sending its shares sharply lower in afternoon trading.

BioCryst tested an intramuscular form of the drug against a placebo as a treatment for seasonal influenza. The difference in recovery time for patients was not statistically significant. Shares of the Birmingham, Ala., company fell 25 cents, or 7.9 percent, to $2.93 in afternoon trading.

The midstage trial included 405 patients. Those who had peramivir injected into their muscles recovered in an average of 91.1 hours, or a bit less than four days. Patients who received a placebo treatment recovered in 106.1 hours.

The company is also developing a form of peramivir that is delivered intravenously, but Leerink Swann analyst Joseph Schwartz said both versions of the drug have been dealt serious setbacks.

"Peramivir has failed several clinical studies," he said. "The intramuscular form looks to be challenged by delivery, and the intravenous form is difficult because there's never been a drug developed for uncomplicated hospital or inpatient influenza," meaning it will be harder to determine the goals of clinical future studies.

The intravenous version of peramivir is intended to be delivered at hospitals or by doctors. The intramuscular form is intended for outpatient use, similar to drugs like Tamiflu and Relenza.

BioCryst is seeking approval for the intravenous version of the drug through a pre-emergency use authorization, which would allow the company to ship the drug to the government for one year as a preventive measure to stop a large flu outbreak. BioCryst said Friday that it is preparing to deliver part of its inventory of the drug, about 1,000 doses, to the Centers for Disease Control and Prevention.

The company also reported its first-quarter financial results. BioCryst narrowed its loss to lost $9.3 million, or 24 cents per share, from $13.1 million, or 34 cents per share, a year ago. Revenue fell to $4.4 million from $10.8 million, but the company cut its expenses nearly in half by reducing research and development costs.

The two analysts reporting to Thomson Reuters were expecting a loss of 28 cents per share and $10.8 million in revenue, on average.
------------------------